Skip to main content
OPCH
NASDAQ Industrial Applications And Services

Option Care Health Q2 2026: Revenue Climbs 1.9% Amid CID Headwinds; Buyback Boosted to $1B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$24.51
Mkt Cap
$3.53B
52W Low
$18.01
52W High
$36.8
52W Position info
36% above low
Off High info
33% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

OPCH sits 36% above its 52-week low of $18.01.

Summary

Option Care Health posted Q2 2026 revenue of $1.44 billion, a 1.9% increase year over year, with diluted EPS of $0.35. Gross margin slipped to 18.5% as CID therapy headwinds persisted. The company raised its share buyback authorization to $1 billion and expanded its credit facility.


Key Events · Earnings and Guidance · OPCH

  • Q2 Revenue and Earnings

    Net revenue reached $1.44 billion, up 1.9% year over year, while net income came in at $53.9 million, or $0.35 per diluted share, compared to $50.5 million, or $0.31 per share, in Q2 2025.

  • Gross Margin Pressure

    Gross profit margin contracted to 18.5% from 19.0% a year ago, pressured by patient attrition and an unfavorable mix within the chronic inflammatory disease portfolio. Management anticipates CID headwinds will reduce gross profit by approximately $55 million in 2026.

  • Capital Allocation

    The board increased the share repurchase authorization to $1.0 billion. During the first half of 2026, the company repurchased 7.9 million shares for $167.5 million at an average price of $21.26, leaving $525 million remaining under the authorization.

  • Liquidity and Credit Facility

    Revolver capacity was expanded by $450 million to $850 million, with $846 million available as of June 30, 2026. Cash from operations surged to $171.5 million in the first half of 2026, driven by inventory reduction.


Analysis · OPCH · Industrial Applications And Services

A solid quarter for Option Care Health featured revenue growth and improved operating income, yet gross margin compression from its chronic inflammatory disease portfolio continues to weigh on results. Confidence in cash generation is evident as the company expanded its revolver and bought back stock aggressively. The projected $55 million CID headwind for 2026 remains a critical watchpoint.

At the time of this filing, OPCH was trading at $24.51 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $18.01 to $36.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OPCH - Latest Insights

OPCH
Jul 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $24.51
Real-time Price: $24.51 info
Change: $0 (0%) info
Market Cap: $3.53B info
OPCH
Jul 29, 2026, 6:56 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.19
Real-time Price: $24.51 info
Change: +$2.32 (+10%) info
Market Cap: $3.53B info
OPCH
May 05, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.25
Real-time Price: $24.51 info
Change: +$3.26 (+15%) info
Market Cap: $3.53B info
OPCH
Apr 30, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $20.22
Real-time Price: $24.51 info
Change: +$4.29 (+21%) info
Market Cap: $3.53B info
OPCH
Apr 30, 2026, 7:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $26.00
Real-time Price: $24.51 info
Change: -$1.49 (-6%) info
Market Cap: $3.53B info